Patients with hematologic malignancies receive less appropriate end-of-life care than patients with solid tumors because of barriers with patients, physicians, and the healthcare system in general, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.
New research shows that carfilzomib in newly diagnosed patients with multiple myeloma resulted in a higher rate of minimal residual disease negativity compared with usual rates, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
The French biotech Servier has an agreement with Allogene Therapeutics, through Pfizer, to market its allogenic chimeric antigen receptor (CAR) T-cell product in the United States if it receives FDA approval.
Symptoms of myeloproliferative neoplasms (MPNs) have a large impact on quality of life for patients and it is important to be able to link them, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Results presented at ASH support giving ibrutinib as first-line therapy in chronic lymphocytic leukemia (CLL), and future results may offer insights on whether patients can stop therapy once they have undetectable minimal residual disease (MRD).
While there are more novel therapies available to treat chronic lymphocytic leukemia (CLL), there are still unanswered questions about how to use these therapies in sequences, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.